TrialJAMA oncology2020

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Richard D Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.